ArticleScientific reports2025
Tuberculosis treatment success rate and its predictors among TB HIV co-infected patients in East and North Eastern Uganda.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tuberculosis notification trends and treatment outcomes in Bangladesh: findings from a National TB Program data, 2019-2021.BMC infectious diseases · 2026Article
- Tuberculosis treatment outcomes and their determinants among patients attending Hargeisa TB Hospital: a five-year retrospective study.The Pan African medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TB/HIV co-infection is associated with poorer treatment outcomes compared to TB alone. This study assessed the TB treatment success rate and its predictors among TB/HIV co-infected patients in East and North Eastern Uganda. A retrospective cohort design was used, involving 324 patients treated between July 2019 and July 2021 at three regional referral hospitals. Treatment success, defined as completing therapy with or without bacteriologic confirmation, was achieved by 71.9% of patients (95% CI 67-77%). Loss to follow-up was 12%, mortality 9.9%, treatment failure 0.3%, and 5.2% were not evaluated. Patients lacking sputum monitoring at five months were significantly less likely to achieve treatment success (aRR 0.48, 95% CI 0.34-0.66). These findings underscore the importance of effective follow-up to improve outcomes for TB/HIV co-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.